文摘
In the present study, a series of steroidal tetrazole derivatives of androstane and pregnane have been prepared in which the tetrazole moiety was appended at C-3 and 17a-aza locations. 3-Tetrazolo-3,5-androstadien-17-one (ass="boldFont">6), 3-tetrazolo-19-nor-3,5-androstadien-17-one (ass="boldFont">10), 3-tetrazolo-3,5-pregnadien-20-one (ass="boldFont">14), 17a-substituted 3-tetrazolo-17a-aza-an class="smallcaps">dan>-homo-3,5-androstadien-17-one (ass="boldFont">26–ass="boldFont">31) and 3-(2-acetyltetrazolo)-17a-aza-an class="smallcaps">dan>-homo-3,5-androstadien-17-one (ass="boldFont">32) were synthesized from dehydroepiandrosterone acetate (1) through multiple synthetic steps. Some of the synthesized compounds were evaluated for their in vitro 5α-reductase (5AR) inhibitory activity by measuring the conversion of [3H] androstenedione in human embryonic kidney (HEK) cells. In vivo 5α-reductase inhibitory activity also showed a significant reduction (p <0.05) in rat prostate weight. The most potent compound ass="boldFont">14 showed 5AR-2 inhibition with IC50 being 15.6 nM as compared to clinically used drug finasteride (40 nM). There was also a significant inhibition of 5AR-1 with IC50 547 nM compared to finasteride (453 nM).